Background on Telintra
Telintra is an investigational agent in development for the treatment of a variety of neoplastic and non-neoplastic hematologic disorders, including myelodysplastic syndrome (MDS), and has demonstrated significant improvement in the induction of growth and differentiation of hematologic precursor stem cells as well as an increase in apoptosis of malignant cells. Telintra is an inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1), a negative regulator of JNK. Treatment of human cells with Telintra leads to the activation of JNK, which promotes the growth and differentiation of hematopoietic stem cell precursors. Telintra treatment has shown significant improvement in neutrophil levels in several clinical trials in MDS. More information about Telintra may be found at www.telik.com.
About Telik, Inc.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating ICN and MDS, whether Telintra treatment results in hematologic improvement in patients with ICN and MDS, and the capability of Telintra to induce apoptosis in malignant cells and treat hematologic disorders in general. These forward-looking statements are based upon Telik's current expectations and there are important factors that could cause actual results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ending June 30, 2011. Telik does not undertake any obligation to update forward looking statements contained in this press release. Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV